Few studies have examined the characteristics of somatic mutations in HRR pathway genes other than BRCA1/2, and the impact of these mutations on treatment efficacy and prognosis in patients with ovarian cancer is not clear. This evidence concerns the gene BRCA1 and ovarian cancer.